柔红霉素与阿糖胞苷、长春新碱和泼尼松联合（ROAP）治疗成人急性白血病。西南肿瘤协作组研究。

Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. A Southwest Oncology Group Study.

作者信息

Morrison F S, Benjamin R, Amare M, Costanzi J J, Hussein K, Ryan D H, Balcerzak S, Pendleton O J

出版信息

Am J Clin Oncol. 1982 Dec;5(6):645-8. doi: 10.1097/00000421-198212000-00013.

DOI:10.1097/00000421-198212000-00013

Abstract

In an 18-month period, 340 consecutive adult patients with acute leukemia were treated using a 7-day continuous infusion of Ara-C in combination with rubidazone, vincristine and prednisone (ROAP). Of 334 (96%) evaluable cases, 77% were 50 years of age or older. The complete remission (CR) rate was 51% with a standard error of 3%. After adjustment for known prognostic factors this overall CR rate is 10% higher than the predicted CR rate when compared to the last completed SWOG study which used adriamycin in combination with a similar regimen of Ara-C, vincristine, and prednisone. The CR rate in patients over 50 years of age was particularly noteworthy. Using rubidazone, the CR rate was 46.1% (116/256) compared to 37.4% (91/243) for the adriamycin study in this poorly responding age group. The median survival time achieved was 27 weeks. However, in the age groups 40-49 years and 50-59 years the median survival was 70 and 44 weeks, respectively.

摘要

在18个月的时间里，对340例连续的成年急性白血病患者采用阿糖胞苷持续输注7天联合柔红霉素、长春新碱和泼尼松（ROAP）进行治疗。在334例（96%）可评估病例中，77%的患者年龄在50岁及以上。完全缓解（CR）率为51%，标准误差为3%。在对已知预后因素进行调整后，与上一项完成的使用阿霉素联合类似阿糖胞苷、长春新碱和泼尼松方案的SWOG研究相比，这一总体CR率比预测的CR率高10%。50岁以上患者的CR率尤其值得注意。使用柔红霉素时，CR率为46.1%（116/256），而在这个反应较差的年龄组中，阿霉素研究的CR率为37.4%（91/243）。达到的中位生存时间为27周。然而，在40 - 49岁和50 - 59岁年龄组中，中位生存时间分别为70周和44周。